The keywords and combinations used were: "antibody-drug conjugates" or "ADC" and "prostate cancer" and "PSMA" or "TROP2" or "STEAP1" or "TF" or "HER2" or "SLC44A4" or "B7-H3" or "CD46" or "TM4FS1" or "DLL-3," with no range date filter. This evidence concerns the gene TACSTD2 and prostate carcinoma.